V. Henschel

发表

Diagnostic performance of the universal visual scoring system (UniViSS) on occlusal surfaces

U. Mansmann, R. Hickel, R. Heinrich-Weltzien, 2010, Clinical Oral Investigations.

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.

A. Schneeweiss, S. Loi, L. Molinero, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.

A. Schneeweiss, S. Loi, H. Rugo, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.

E. Winer, A. Schneeweiss, S. Loi, 2019, The Lancet. Oncology.

Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial.

T. Strowitzki, M. von Wolff, V. Henschel, 2006, The Journal of clinical endocrinology and metabolism.

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

M. Parmar, J. Mackey, D. Cameron, 2013, The Lancet. Oncology.

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

M. Buyse, J. Mackey, N. Robert, 2013 .

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis.

M. Reiser, G. Steinbeck, B. Wintersperger, 2010, International journal of cardiology.

G-CSF in patients suffering from late revascularised ST elevation myocardial infarction: final 1-year-results of the G-CSF-STEMI Trial.

S. Schoenberg, G. Steinbeck, B. Wintersperger, 2010, International journal of cardiology.

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

C. Barrios, J. Huober, V. Graupner, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

M. Socinski, A. Shaw, S. Ou, 2016, The Lancet. Oncology.

Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)

R. Burger, M. Birrer, S. Scherer, 2012 .

A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).

M. Socinski, A. Shaw, S. Ou, 2015 .

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer

M. Socinski, A. Shaw, Gregory Riely, 2015, The Lancet. Oncology.

Statistical inference in simplicially contoured sample distributions

V. Henschel, 2002 .

Geometric Generalization of the Exponential Law

W. Richter, V. Henschel, 2002 .

Exact distributions in the model of a regression line for the threshold parameter with exponential distribution of errors

Volkmar Henschel, V. Henschel, 2001, Kybernetika.

IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

E. Winer, A. Schneeweiss, S. Loi, 2019, Journal of Clinical Oncology.

Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC).

E. Winer, A. Schneeweiss, S. Loi, 2019, Journal of Clinical Oncology.

Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer

E. Winer, A. Schneeweiss, S. Loi, 2018, The New England journal of medicine.

Epidemiology and quality control of 245 000 outpatient colonoscopies.

A. Crispin, U. Mansmann, A. Munte, 2008, Deutsches Arzteblatt international.

Conservative therapy in patients with anterior disc displacement without reduction using 2 common splints: a randomized clinical trial.

M. Schmitter, P. Rammelsberg, V. Henschel, 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

The vital threat of an upper gastrointestinal bleeding: Risk factor analysis of 121 consecutive patients.

C. Herfarth, Genevieve Dei-Anane, P. Schemmer, 2006, World journal of gastroenterology.

Impact of serum creatinine measurement error on dose adjustment in renal failure

W. Haefeli, U. Mansmann, V. Henschel, 2003, Clinical pharmacology and therapy.

A semiparametric Bayesian proportional hazards model for interval censored data with frailty effects

Ulrich Mansmann, Volkmar Henschel, Jutta Engel, 2009, BMC medical research methodology.

Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population.

K. Bogman, M. Martin-Facklam, P. N. Morcos, 2016 .

In vitro leakage associated with three root-filling techniques in large and extremely large root canals.

S. Friedman, V. Henschel, H. Staehle, 2007, Journal of endodontics.

Validity of temporomandibular disorder examination procedures for assessment of temporomandibular joint status.

M. Schmitter, B. Kress, P. Rammelsberg, 2008, American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics.

Serum concentrations of cortisol, interleukin 6, leptin and adiponectin predict stress induced insulin resistance in acute inflammatory reactions

B. Göke, M. Vogeser, E. Kilger, 2008, Critical care.

Prediction of TMJ arthralgia according to clinical diagnosis and MRI findings.

Peter Rammelsberg, Bodo Kress, M. Schmitter, 2006, The International journal of prosthodontics.

Abnormal Motor Cortex Excitability in Congenital Stroke

V. Brodbeck, S. Berweck, M. Staudt, 2008, Pediatric Research.

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer

A. Schneeweiss, S. Loi, H. Iwata, 2020, Annals of Oncology.

Reproducibility of DIAGNOdent 2095 and DIAGNOdent Pen measurements: results from an in vitro study on occlusal sites.

R. Hickel, J. Kühnisch, K. Bücher, 2007, European journal of oral sciences.

Short‐term effects of treatment‐induced hormonal changes on cognitive function in breast cancer patients

M. Lux, I. Bauerfeind, M. Untch, 2008, Cancer.